StockIQ.techAstraZeneca PLC (AZN.L) Stock Analysis
Free AI-powered analysis and research for AstraZeneca PLC stock
Sector: Healthcare
AZN.L snapshot
Data as of 3 Nov 2026 close. Updated daily.
AstraZeneca PLC scores 75/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 66% of its 52-week range, up 11.3% over the past year. Latest reported figures show a profit margin of 17.0%, return on equity of 22.0% and revenue growth of +6.4%.
What is driving the score
- Strong Uptrend: +12
- MACD Bullish: +8
- Good Profit Margin (17.0%): +5
- Low Liquidity (0.89 Current Ratio): -10
- Excellent ROE (22.0%): +8
- High P/B (5.39): -5
- Above MA200: +4
- Up Over 1 Year (+11.3%): +3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full AZN.L report
AstraZeneca PLC (AZN.L) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze AZN.L Now →📰 Latest Update
RNA Targeting Small Molecule Drug Discovery Market - Global Strategic Business Report: Secure a US$5.3B Market by 2030 as Amgen, AstraZeneca, Roche and Merck Accelerate RNA Pipelines
Mon, November 2, 2026 at 3:50 PM UTC 3 min read
The global RNA targeting small molecule drug discovery market, valued at US$1.8 billion in 2024, is projected to reach US$5.3 billion by 2030, growing at a CAGR of 19.9%. Key players like AstraZeneca, Amgen, Roche, and Merck are accelerating their RNA-focused pipelines, driven by advancements in AI, structural biology, and high-throughput screening. The report highlights the increasing importance of RNA in therapeutic development across various diseases, including cancer and infectious diseases, and emphasizes the growing partnerships within the sector.